Dynavax Announces HEPLISAV-B™ is Now Available in the United States for the Prevention of Hepatitis B in Adults

HEPLISAV-B is the First and Only Two-Dose Vaccine in U.S. for Hepatitis B Prevention in Adults BERKELEY, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] is now available in the United States for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. HEPLISAV-B was approved

U.S.: Dynavax Announces FDA Approval of HEPLISAV-B™ for Prevention of Hepatitis B in Adults

First and Only Two-Dose Vaccine in United States for Prevention of Hepatitis B in Adults. First New Hepatitis B Vaccine in United States in More than 25 Years.  BERKELEY, CA--(Marketwired - November 09, 2017) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hep